Gear up for AACR24!

See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥

$Arcellx (ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics (ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics (BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals (CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals (DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics (FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals (FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: GC012F (Ph 1/2)
$Inhibrx (INBX.US)$ : INBRX-109 (Ph 2)
$RAPT Therapeutics (RAPT.US)$ : Tivumecirnon (Ph 2)
$Arcus Biosciences (RCUS.US)$ : Domvanalimab (Ph 2/3)
$Relay Therapeutics (RLAY.US)$ : RLY-4008 (Lirafugratinib) (Ph 1/2)
$Sutro Biopharma (STRO.US)$ : Luveltamab Tazevibulin (Ph 2/3)
$SpringWorks Therapeutics (SWTX.US)$ : Nirogacestat (Ph 2)
$Zymeworks (ZYME.US)$ : Zanidatamab (BLA)